Abbott, already the title sponsor of the Abbott World Marathon Majors, recently added another running sponsorship to its ever-expanding portfolio.
Despite strong contributions from fingerstick-free blood glucose monitor Freestyle Libre and mitral valve repair device MitraClip--medical devices remained the worst performing business for Abbott Laboratories last quarter as sales climbed 3.1% on an operational basis to $1.3 billion.
Give a whoop for Abbott Laboratories' buyout of CFR Pharmaceuticals. That deal helped boost the company's generics sales for the second quarter to $977 million, up by 31%. The generics unit now accounts for 21% of Abbott's overall sales.
The U.S. Food and Drug Administration has approved the iDesign Advanced WaveScan Studio System from Abbott Laboratories. The company has already launched the system, which is based on a 3-D map of the eye that's expected to improve the accuracy of Lasik procedures.
Social media success in consumer marketing has advanced beyond counting fans and followers. Today it's all about shares, retweets and links that indicate real consumer engagement with brands....
Summer music festival goers may see a new face this year among the beer and souvenir tents. Pedialyte, Abbott Laboratories' electrolyte drink for sick kids, is joining the summer fun circuit to hand out samples as an antidote for overindulgence.
FiercePharmaAsia combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.
Major Western device and medical technology firms launched Asia Pacific Medical Technology Association, or APACMed, pledging the association would unite a fragmented effort to work with regulators across a region that is both lucrative and frustrating on issues ranging from import rules to public tender guidelines.
Diabetes care at Abbott Laboratories has returned to sales growth as ex-U.S. sales of its new FreeStyle Libre kick in and the impact of diabetes device reimbursement reductions dropped off the books. The continuous glucose monitor eliminates regular finger sticks and has surpassed the company's sales expectations.
New Enterprise Associates has closed a pair of funds totaling $3.15 billion to invest in information technology and healthcare companies. And while med tech may not loom particularly large for NEA, the firm does have roughly a couple of dozen active medical device portfolio companies.